ICON8 TRIAL

ICON8 is a randomised three-arm, three stage Gynaecologic Cancer InterGroup (GCIG) phase III trial designed to evaluate the safety and efficacy of dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy in the treatment of patients with ovarian cancer... Combination chemotherapy with carboplatin and paclitaxel given once every three weeks is an internationally recommended regimen for the first-line treatment of ovarian cancer (standard treatment). There is a growing body of evidence that giving these agents weekly may be more effective (dose-fractionated chemotherapy). In ICON8 two different dose-fractionated regimens are compared with standard chemotherapy: weekly paclitaxel given with standard three-weekly carboplatin; and weekly carboplatin and paclitaxel.

Also known as: ICON8 Trials Programme

Primary location: London United Kingdom